A study by Tumeh et al.19 found that preexisting CD8+ T cells are essential for tumor regression following therapeutic PD-1/PD-L1 blockade in metastatic melanoma, indicating that CD8+ TILs play a key role in anti-PD-1 therapy response. Here, CD8A is linked to neoplasm.